Now available OPDUALAG™ 

OPDUALAG™ (nivolumab and relatlimab-rmbw) injection, for intravenous use, is a combination of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody, indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.

Please see the full prescribing information.